These Asian results are derived from a global review of pharma's corporate reputation (conducted November 2016 to early-February 2017).
The Asian results form the opinions of 98 patient groups: 42 came from Australasia; 11 from Central Asia; 27 from East Asia; 5 from South Asia; and 13 from South-East Asia.
16 pharma companies are included in this 2016 Asian analysis:
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly
- Merck & Co
- Novo Nordisk
How pharma is assessed for corporate reputation
- How the pharma industry’s corporate reputation compares with that of other healthcare industries.
- How the pharma industry’s corporate reputation has changed over the past five years.
- How good or bad the pharma industry is at various activities of relevance to patients and patient groups.
7 indicators show the corporate reputation of individual pharma companies:
- Patient centricity.
- Information for patients.
- Patient safety.
- Usefulness of products.
- Patient-group relationships (new for 2016).
[On transparency] “Perhaps ask the external stakeholders for feedback, and publish the results.”— Local osteoporosis patient group, Australia
[On patient-group relations] “Communicate with our patient group when applications are being made to government agencies, re medicines relevant to our condition. Support information and events, to help inform medical practitioners, patients and families about best practice.”— National rare-condition patient group, New Zealand
[On patient information] “It seems that it is not a patient-centered medical treatment, but a doctor-centered medical treatment. I would like you to arrange a system to listen to the patient’s voice in some form, convince
society in general (including medical professionals), and change from the current system to patient-centered medical care.”— National lymphoedema and breast-cancer patient group, Japan
- Asian patient groups were more positive about the pharma industry’s corporate reputation than patient groups worldwide. In 2016, as many as 49.46% of Asian patient groups thought that the pharma industry had an “Excellent” or “Good” corporate reputation, compared with just 37.9% of patient groups from across the world. Asian patient groups ranked pharma 1st in 2016 among eight healthcare-industry sectors for having an
- “Excellent” or “Good” corporate reputation. By contrast, patient groups from all geographic areas ranked pharma 5th in 2016.
- Asian patient groups were more positive about many of the pharma industry’s activities (with the exception of innovation).
- How can pharma improve its corporate reputation? When respondent Asian patient groups were asked to single out the one activity most likely to help pharma improve its corporate reputation, 17% nominated fair pricing, 16% picked patient centricity, and 13% suggested having good relationships with patient groups.
THE RELATIONSHIPS BETWEEN PHARMA COMPANIES AND PATIENT GROUPS
- The company with which Asian patient groups were most familiar was Pfizer (66% of respondent Asian patient groups were familiar with Pfizer). Followed by Novartis (at 60%).
INDIVIDUAL COMPANY FINDINGS
Results among patient groups familiar with the company
- AbbVie ranked overall 1st for corporate reputation among Asian patient groups familiar with it. AbbVie also ranked 1st for three of the seven indicators of corporate reputation: patient centricity; transparency; and patient-group relations.
- GSK ranked 1st for the provision of high-quality patient information.
- Novo Nordisk ranked 1st for patient safety, for the provision of high-quality products, and for integrity (Novo Nordisk’s favourable results were mostly driven by the respondent Asian haemophilia patient groups).
Results among patient groups that work with the company
- GSK was positioned overall 1st for corporate reputation by its Asian patient-group partners. They also placed GSK 1st for five of the seven indicators of corporate reputation (the exceptions were patient centricity, and patient-group relations).
- Eli Lilly was positioned 1st for patient centricity by its patient-group partners.
- Novartis was positioned 1st for patient-group relations by its patient-group partners.
Asian patient-group relationships with pharma.
Industry-wide findings from Asian patient groups.
Asian patient groups on improving corporate reputation.
Rankings of the 16 pharma companies among Asian patient groups FAMILIAR with them.
Positioning of the 16 pharma companies among PARTNER Asian patient groups.
Profiles of the 16 pharma companies.
Comments from respondent Asian patient groups.
Profile of the 98 respondent
Asian patient groups.
Rankings among Asian patient groups for the indicators of corporate reputation among patient groups familiar with the company, and which work/partner with the company, 2016.
The company's average scores for the 7 indicators of corporate reputation, 2016 versus 2015.
The company’s performance for the 7 indicators of corporate reputation, 2016.
The company’s rankings among patient groups for the indicators of corporate reputation, 2016: Asia versus therapy wide; familiar with versus worked with.
Percentage of the patient groups that worked with the company—but which also worked with other companies, 2016.
How the company did at corporate reputation in different countries/therapy areas, compared with its Asian average, 2016.